Skip to content
Medical Health Aged Care

QPS Announces New Laboratory Services for Clinical Trials and Cell Therapy Development

QPS Holdings, LLC 3 mins read
NEWARK, Del.--BUSINESS WIRE--

QPS, a leading global contract research organization (CRO), is pleased to announce new laboratory services capabilities. The central laboratory, leukopak cell therapy facility, and enhanced PBMC capabilities will complement existing bioanalysis, translational medicine and peripheral blood mononuclear cell (PMBC) laboratories and extend the current QPS full-service global CRO offerings.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240626261072/en/

QPS Missouri, a division of QPS Holdings, LLC, a global Contract Research Organization. QPS Missouri conducts Phase I-IV clinical trials and houses central lab, safety lab, PBMC and cell production services in Springfield, Missouri. (Photo: Business Wire)

QPS Missouri, a division of QPS Holdings, LLC, a global Contract Research Organization. QPS Missouri conducts Phase I-IV clinical trials and houses central lab, safety lab, PBMC and cell production services in Springfield, Missouri. (Photo: Business Wire)

QPS now offers clinical trial sample analysis services and leukopak cell therapy products from its newly expanded clinical trials unit conveniently located in Springfield, Missouri. In addition, QPS has also expanded PBMC service offerings from its Miami, Florida location into its Springfield, Missouri laboratories. The new facilities are housed with an existing clinical (safety) laboratory, a modern self-contained pharmacy, and dedicated space to build and ship clinical trial kits.

The modern central laboratory for sample analysis complements the existing on-site safety laboratory, equipped with the most up-to-date technologies for chemistry, urinalysis, serology, coagulation, and hematology testing. These capabilities, designed to monitor subject safety during ongoing clinical trials, will remain as core services for QPS in-house clinical trials.

The new leukopak products collection and processing facility is designed to meet the exponential growing demand for blood products to support cell therapy research and QPS is ideally placed to provide this service. QPS Missouri has a database of over 35,000 potential study participants, who can be contacted as potential blood donors for leukopak products.

“There is significant unmet demand in this rapidly growing area of cell therapy products, which represents a tremendous opportunity for QPS. Over 3,000 cell and gene therapy programs are currently in progress representing a 20% increase over the past five years. These programs require leukopak products to move forward, and as a result this market is forecasted to grow by a CAGR of more than 8% over the next six years,” said Benjamin Chien, Chairman, President and CEO of QPS.

The enhanced PBMC services include a new PBMC processing lab at the Springfield location, complementing the existing lab at QPS Miami in Miami, Florida. This new lab will support a current unmet need for PBMC processing in the midwestern USA. PBMC sample analysis is a time-consuming process, typically required in vaccine trials, and it is best done in a lab adjacent to the clinical trial unit. QPS is uniquely positioned to offer this service.

“These new facilities, services and products extend our full service CRO capabilities, putting QPS in a position to offer clients comprehensive clinical research services in one location. The central lab, PBMC lab, and the leukopack facility complement and enhance our current 240 bed clinical trials unit, safety laboratory, modern self-contained pharmacy, and clinical trial kit production facility,” said Brendon Bourg, Vice President, Early Phase Clinical and Head of Administration at QPS Missouri.

ABOUT QPS HOLDINGS, LLC

QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,100+ employees in the US, Europe, and Asia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, and turnkey laboratories and facilities. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers. For more information, visit www.qps.com or email info@qps.com.


Contact details:

Gabrielle Pastore
1-302-635-4290
Gabrielle.Pastore@qps.com

Media

More from this category

  • Federal Budget, Medical Health Aged Care
  • 26/03/2025
  • 13:55
Australia New Zealand Gynaecological Oncology Group (ANZGOG)

ANZGOG welcomes the Federal Budget’s investment in medical research and clinical trials and highlights the need for continued focus on gynaecological cancers

MEDIA RELEASEFOR IMMEDIATE RELEASE The Australia New Zealand Gynaecological Oncology Group (ANZGOG) welcomes key initiatives in the Federal Budget that will support Australians living with gynaecological cancer. This includes investment in medical research, clinical trials, Pharmaceutical Benefits Scheme (PBS), Medicare and support for our healthcare workers. ANZGOG acknowledges the Federal Government’s commitment of $158.6 million over five years to support medical research and the translation of research into clinical practice, alongside the $150.3 million investment in expanding precision oncology programs, including the Australian Rare Cancers Portal. These investments represent a positive step in strengthening Australia’s healthcare system and advancing cancer…

  • Medical Health Aged Care
  • 26/03/2025
  • 12:22
Royal Australian College of GPs

GPs back Meningococcal B vaccine call

The Royal Australian College of GPs (RACGP) has thrown its support behind 10 Independent NSW MPs calling on the State Government to boost Meningococcal B vaccination rates. The push follows a similar RACGP call made earlier this year, when it urged the Government to protect families across the state by providing free Meningococcal B vaccines to at-risk groups, including children aged two-and-under, and every teen aged 15-19-years-old.   RACGP NSW and ACT Chair, Dr Rebekah Hoffman, backed the call for action. “By providing the Meningococcal B vaccine free of charge for at-risk groups we can save lives across the state,” she…

  • Government NSW, Medical Health Aged Care
  • 26/03/2025
  • 10:50
HSU NSW

MEDIA ALERT: Allied health workers to rally at Westmead Hospital to call attention to workforce crisis

Allied health workers rally at Westmead Hospitalto call attention to workforce crisis More than 200 allied healthcare workers will rally at Sydney'sWestmead Hospital on Thursday in response to the workforce retention crisis putting pressure on clinicians and patients. Health Services Union members are celebrating the invaluable work of allied health practitioners, and campaigning for measures to attract and retain clinicians who are vital to the health of western Sydney. “Allied health workers play a critical role in our stretched health care system, and we are at risk of losing these clinicians if we don’t shake things up,”HSU Secretary Gerard Hayes…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.